Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Literature
1.
Pan Wei, Kang Yongbo (2018) Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int Urol Nephrol 50:289–299CrossRefPubMed
2.
Mydlik M, Derzsiova K (2010) Oxalic acid—important uremic toxin. Vnitr Lek 56:695–701PubMed
3.
Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW (2011) Factors related to colonization with Oxalobacter formigenes in U.S. adults. J Endourol 25:673–679CrossRefPubMedPubMedCentral
4.
Turkmen K, Erdur FM (2015) The relationship between colonization of Oxalobacter formigenes serum oxalic acid and endothelial dysfunction in hemodialysis patients: from impaired colon to impaired endothelium. Med Hypotheses 84(3):273–275CrossRefPubMed
5.
Gulhan B, Turkmen K, Aydin M, Gunay M, Cıkman A, Kara M (2015) The relationship between serum oxalic acid, central hemodynamic parameters and colonization by oxalobacter formigenes in hemodialysis patients. Cardiorenal Med 5(3):164–174CrossRefPubMedPubMedCentral
6.
Kalantar-Zadeh K, Kopple JD, Deepak S, Block D, Block G (2002) Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 12:17–31CrossRefPubMed
Metadata
Title
The importance of Oxalobacter formigenes and oxalic acid in the pathogenesis of chronic kidney disease
Authors
Ismail Baloglu
Kultigin Turkmen
Publication date
01-06-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1848-3

Other articles of this Issue 6/2018

International Urology and Nephrology 6/2018 Go to the issue

Nephrology - Review

Betel nut chewing and the risk of chronic kidney disease: evidence from a meta-analysis

Nephrology - Original Paper

Health-related quality of life in end-stage renal disease patients: the effects of starting dialysis in the first year after the transition period

Nephrology - Review

Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment

Nephrology - Original Paper

Effect of socio-demographic factors on endogenous biomarkers (cystatin C and creatinine) among elderly chronic kidney disease patients: a cross-sectional study

Urology - Original Paper

Silymarin and celecoxib ameliorate experimental varicocele-induced pathogenesis: evidences for oxidative stress and inflammation inhibition

Nephrology - Original Paper

Diversity of the midstream urine microbiome in adults with chronic kidney disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits